Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia

被引：0
作者：
Mushtaq, Muhammad Umair [1 ,2 ]
Chaudhary, Sibgha Gull [1 ,2 ]
Michaelis, Laura C. [3 ]
Carlson, Karen-Sue B. [3 ]
Abedin, Sameem [3 ]
Runass, Lyndsey [3 ]
Fallon, Michael J. [1 ,2 ]
Harrington, Alexandra M. [4 ]
Juckett, Mark [2 ,5 ]
Hall, Aric C. [1 ,2 ]
Mattison, Ryan J. [1 ,2 ]
Atallah, Ehab L. [3 ]
Murthy, Guru Subramanian Guru [3 ]
机构：
[1] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Hematol Oncol, Madison, WI USA
[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[3] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA
[4] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
[5] Univ Wisconsin, Sch Med & Publ Hlth, Div Hematol Oncol, Madison, WI USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-113764
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2708
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies
    Bertoli, Sarah
    Tavitian, Suzanne
    Berard, Emilie
    Gadaud, Noemie
    Luquet, Isabelle
    Huynh, Anne
    Sarry, Audrey
    Huguet, Francoise
    Recher, Christian
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 238 - 241
  • [42] Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
    Cummins, K. D.
    Jane, S. M.
    Ninkovic, S.
    Bazargan, A.
    Filshie, R.
    Sutrave, G.
    Hertzberg, M.
    Scott, A.
    Lane, S.
    Yannakou, C. K.
    Ritchie, D.
    D'Rozario, J.
    Black, J.
    Bavishi, K.
    Wei, A.
    [J]. BLOOD CANCER JOURNAL, 2014, 4 : e237 - e237
  • [43] IMPACT OF THE COMPOSITION OF SALVAGE REGIMENS ON RESPONSE AND OVERALL SURVIVAL IN PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA
    Wattad, M.
    Doehner, K.
    Krauter, J.
    Gaidzik, V. I.
    Paschka, P.
    Heuser, M.
    Thol, F.
    Kindler, T.
    Luebbert, M.
    Salih, H. R.
    Kuendgen, A.
    Horst, H. A.
    Brossart, P.
    Goetze, K.
    Nachbaur, D.
    Koehne, C. H.
    Ringhoffer, M.
    Wulf, G.
    Held, G.
    Salwender, H.
    Benner, A.
    Ganser, A.
    Doehner, H.
    Schlenk, R.
    [J]. HAEMATOLOGICA, 2014, 99 : 526 - 526
  • [44] Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
    K D Cummins
    S M Jane
    S Ninkovic
    A Bazargan
    R Filshie
    G Sutrave
    M Hertzberg
    A Scott
    S Lane
    C K Yannakou
    D Ritchie
    J D'Rozario
    J Black
    K Bavishi
    A Wei
    [J]. Blood Cancer Journal, 2014, 4 : e237 - e237
  • [45] Infectious Complications in Patients with Relapsed Acute Myeloid Leukemia (AML) Receiving Clofarabine Versus Fludarabine-Containing Salvage Chemotherapy Regimens
    Mathisen, Michael S.
    Kantarjian, Hagop M.
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Faderl, Stefan
    Borthakur, Gautam
    Cortes, Jorge E.
    Quintas-Cardama, Alfonso
    [J]. BLOOD, 2012, 120 (21)
  • [46] Venetoclax in Combination with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Is Comparable to Alternative Regimens
    Miller, Jenn
    Shannon, Lindsey
    Finch, Amanda
    Altman, Jessica K.
    Wojenski, Daniel
    [J]. BLOOD, 2020, 136
  • [47] Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia
    Westhus, Jonas
    Noppeney, Richard
    Schmitz, Christine
    Flasshove, Michael
    Duehrsen, Ulrich
    Hanoun, Maher
    [J]. ACTA HAEMATOLOGICA, 2020, 143 (05) : 438 - 445
  • [48] Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam M.
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Benton, Christopher B.
    Benton, Christopher B.
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa E.
    Jain, Nitin
    Kornblau, Steven M.
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias
    Masarova, Lucia
    Rytting, Michael E.
    Thompson, Philip A.
    Wang, Sa A.
    Konoplev, Sergej
    Chen, Zhining
    Goswami, Maitrayee
    Maduike, Rita
    Guerrero, Julio A.
    Zhang, Qi
    Cavazos, Antonio
    Ma, Helen
    Bivins, Carol A.
    Wade, Allison
    Adewale, Shadiat L.
    Tse, Susan
    Thomas, Robin
    Vaughan, Kenneth
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    [J]. BLOOD, 2019, 134
  • [49] Azacytidine and Venetoclax as a Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia: A Single Centre Experience
    Mondal, Saikat
    Gupta, Deepika
    Vairamoorthy, Naveen
    Moule, Priyanka
    Kotwal, Jyoti
    Gupta, Nitin
    [J]. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025, 41 (01) : 197 - 199
  • [50] Hypomethylating Agent/Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia
    Jamy, Omer Hassan
    Worth, Sarah
    Rangaraju, Sravanti
    Bachiashvili, Kimo
    Vachhani, Pankit
    Bhatia, Ravi
    [J]. BLOOD, 2021, 138
12345